best glp-1 provider Featured Program 2026 Refills GLP-1 Weight Loss Claims

& STEP 5 Study Group

Clearly positive for patients, especially those with high out-of-pocket costs

Conclusion: Not losing weight on GLP-1 drugs can be frustrating, but its important to remember that weight loss is rarely linear

Tirzepatide, the newest dual GLP-1/GIP receptor agonist, has a similar 5-day half-life, but limited data suggest potentially less gastric emptying delay compared to pure GLP-1 agonists due to dual receptor activation [30]

The side effect profile is dose-dependent, predictable, and in most cases manageable with proper preparation

The Medicare GLP-1 Bridge Program is a CMS demonstration that gives eligible Medicare Part D beneficiaries access to Wegovy, Zepbound, and Foundayo for a $50 per month medication copay for chronic weight management